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Introduction. Microfragmented adipose tissue (MFAT) has been shown to benefit osteoarthritic patients by reducing pain and
supporting tissue regeneration through a mesenchymal stem cell (MSC)-related paracrine mechanism. This observational study
of 110 knees assessed patient-centered outcomes of pain, functionality, and quality of life, analyzing their variation at twelve
months following one ultrasound-guided intra-articular injection of autologous MFAT for the treatment of knee osteoarthritis
(KOA). Method. Inclusion criteria were as follows: VAS >50, and the presence of KOA as diagnosed on X-ray and MRI.
Exclusion criteria included the following: recent injury (<3 months) of the symptomatic knee, intra-articular steroid injections
performed within the last three months, and hyaluronic acid injections prior to this treatment. Changes in VAS, OKS, and EQ-5D
were scored at baseline and twelve months following a single intra-articular injection of autologous MFAT. Score variation was
analyzed utilizing a nonparametric paired samples Wilcoxon test. The statistical analysis is reproducible with Open Access
statistical software R (version 4.0.0 or higher). The study was carried out with full patient consent, in a private practice setting.
Results. Median VAS (pain) improved from 70 (IQR 20) to 30 (IQR 58) (p < 0:001); median OKS (function) improved from 25
(IQR 11) to 33.5 (IQR 16) (p < 0:001); and median EQ-5D (quality of life) improved from 0.62 (IQR 0.41) to 0.69 (IQR 0.28)
(p < 0:001). No adverse events were reported during the intraoperative, recovery, or postoperative periods. Conclusions. For
patients with all grades of knee osteoarthritis who were treated with intra-articular injections of MFAT, statistically significant
improvements in pain, function, and quality of life were reported. Although further research is warranted, the results are
encouraging and suggest a positive role for intra-articular injection of MFAT as a treatment for knee osteoarthritis.
1. Introduction
Osteoarthritis (OA), the most prevalent form of arthritis, is
characterized by chronic progressive degeneration and alter-
ation of hyaline articular cartilage, subchondral bone,
ligaments, capsule, synovium, and periarticular muscles [1].
The condition currently presents a substantial global socio-
economic burden and remains a leading cause of disability,
particularly among the elderly population [2].
With an ageing population, this is a growing problem and
is set to become the fourth leading cause of disability by the
end of 2020 [3, 4]. In the UK, approximately one in seven
people suffer with arthritis. This equates to ten million indi-
viduals. It is a complex and multifactorial disease involving
genetic, environmental, and mechanical causes [5]. The dis-
ease can be classified into one of two groups depending upon
its aetiology: primary (idiopathic or nontraumatic) and sec-
ondary (a result of trauma or mechanical malalignment) [6].
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Advancements in regenerative medicine over the last
decade have revealed the potential for mesenchymal stem
cells (MSCs) to be used as a powerful therapeutic tool against
tissue damage and degeneration [7–9]. Mesenchymal stem
cells (MSCs), more recently termedMedicinal Signaling Cells
[10], have shown promise as a standalone treatment for OA,
or as an adjunct to traditional surgical correction of the
mechanical environment. Since their discovery by Frieden-
stein in the late 1960s [11], extensive research has been
implemented in an effort to exploit these cells for their true
therapeutic potential.
The cells arise from pericytes that are found naturally
occurring around the vasculature in various tissues through-
out the body. Upon disruption of the stromal vascular frac-
tion of tissue, a significant proportion of pericytes lift from
the surface of the vessels and contribute to the tissue homeo-
static response as the source of adipose-derived stem cells-
MSCs [12, 13].
These MSCs respond by producing bioactive signaling
molecules which act in a paracrine fashion to exhibit immu-
nomodulatory, antimicrobial, angiogenic, and trophic/regen-
erative effects on tissue [5, 14]. This ultimately results in
localized and tissue-specific change that encourages regener-
ation and healing [10].
Sources for MSCs include bone marrow, placenta, and
dental pulp [15]. The use of such cells in biological therapy
has always been hindered as they are challenging to obtain
in large enough quantities to provide significant clinical ben-
efit. Additionally, the extraction of such cells from bone mar-
row is a painful procedure, and a 1ml sample provides only
0.01% of MSCs. Conversely, adipose tissue has been recog-
nized as a reliable and potent source for MSCs. One MSC
can be obtained per 100 adipose cells, in contrast to 1 MSC
for every 100,000 bone marrow cells [16–18]. A promising
feature of adipose-derived MSCs is in their localization as
they represent 10-30% of normal body weight and produce
a concentration of 5,000 cells per gram of tissue obtained
[5, 19]. The use of adipose-derived MSCs is associated with
minimal side effects arising and previous studies have shown
no complications relating to malignancy or cancer [20]. It has
also been suggested that these adipose-derived MSCs have
multilineage potential and possess the same regenerative
capacity as those derived from other tissues. Furthermore,
the cells are not adversely influenced by the age of the patient;
a factor that is very beneficial for an elderly population [21].
Given that arthritis is such a prevalent condition, espe-
cially among an ageing population [22], it is vital to identify
the long-term efficacy of therapies that utilize the regenera-
tive power of adipose-derived MSCs, and whether they can
potentially prevent replacement surgery or delay it for as long
as possible. Furthermore, it is important to identify whether
treatment with adipose-derived MSCs, or as in this case,
MFAT-containingMSCs (originating from the adipose blood
vessels as pericytes, and that are released and primed during
the extraction process through sheer stress and microfiltra-
tion of the fat) [23, 24] would be beneficial in providing an
optimal biological environment for healing when used in
conjunction with surgery [25]. Their use for the treatment
of knee osteoarthritis (KOA) has produced very encouraging
results [26–28]. This case series aims to assess the response of
our patient cohort over a one-year period following a routine
single ultrasound-guided intra-articular injection of MFAT
for all grades of KOA.
2. Method
The study was conducted in accordance with the principles of
Good Clinical Practice (NIHR) and the General Medical
Council (GMC) guidelines on research, patient consent to
research and future publication, as well as adhering to and
in accordance with the Declaration of Helsinki. The study
was carried out in a private practice setting.
This observational, intention-to-treat study included the
complete sample of 110 patients who agreed to be scored for
pain (Visual Analogue Scale—VAS), function (Oxford Knee
Score—OKS), and quality of life (EuroQol-5D—EQ-5D) at
baseline regardless of subsequent changes to adherence or
status during follow-up. All patients attended the private
clinics of the authors (AW, NH) complaining of knee pain
following a diagnosis of knee osteoarthritis.
Patients underwent clinical review and examination by
an orthopaedic surgeon. The preoperative assessments
included evaluation of imaging (X-ray in all cases and MRI
in some) where the KOA was graded using the Kellgren &
Lawrence (KL) grading system.
Inclusion criteria included VAS >50, no deformity
greater than ten degrees of varus or valgus, and the presence
of KOA as diagnosed on X-ray and/or MRI. Exclusion cri-
teria included recent injury (<3 months) of the symptomatic
knee, infectious joint disease, malignancy, pregnancy, antic-
oagulation or thrombocytopenia, coagulation disorder, and
intra-articular steroid injections performed within the last
three months. None of our patients had hyaluronic acid
injections prior to this treatment.
The patients were informed of all possible options for
treating their KOA including conservative means as well as
injections of a number of substances including steroids,
hyaluronic acid, platelet-rich plasma, and microfragmented
adipose tissue. They also had surgical options detailed to them
including osteotomy, partial and total knee replacement.
By study design, the paired samples have been selected
and not randomized, so we could not assume a Gaussian dis-
tribution. For this reason, scores variation has been analyzed
utilizing a nonparametric paired samples Wilcoxon test to
assess statistically significant changes in the VAS, OKS, and
EQ-5D scores before and after treatment at twelve months.
For the same reason, summary statistics report median and
interquartile ranges (IQR).
Summary statistics, statistical analysis, and statistical
significance testing are reproducible with Open Access statis-
tical software R (version 4.0.0 or higher; R function Wilcox
test). Figures 1, 2, and 3 have been generated automatically
from data by Open Access statistical software R (version
4.0.0 or higher; libraries ggpubr and Paired-Data); Table 1
summarizes the change in the median VAS, OKS, and
EQ-5D scores at 12 months from baseline according to
the OA grading. Data points are missing at random (12%)
due to patients lost-to-follow-up; missing data have been
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estimated probabilistically with uncertainty (unbiased)
using the statistical software package Amelia v1.7.6 or
higher. The estimation procedure is replicable and repro-
ducible with Open Access statistical software R (4.0.0 or
higher). The missingness map is visualized in Figure 4.
2.1. Patients. The series of 110 cases was comprised of 60
male and 50 female patients, with ages ranging from 42 to
94. Most of the patients had advanced KOA with 80% having
a Kellgren-Lawrence (KL) grade of III or IV. 95 (96.4%) of
the patients had idiopathic KOA, and 4 (3.6%) had posttrau-







Figure 1: VAS scores at baseline and at twelve months follow-up.
y-axis: Visual Analogue Scale (VAS) for pain value; boxplot
showing L-estimators: maximum (100), minimum (50), median
(70), and interquartile range (20); outliers plotted as individual
points at baseline and maximum (100), minimum (0), median
(30), and interquartile range (58); outliers plotted as individual
points at 1 year follow-up. x-axis: Visual Analogue Scale (VAS) for
pain at preoperative baseline and at twelve months follow-up.
Connecting lines: heuristic visualization of single-patient trajectories
of variation of Visual Analogue Scale (VAS) value for pain between
preoperative baseline and twelve months follow-up; plotted with R
(version 4.0.0 or higher; libraries ggpubr and PairedData). Source:
Authors’ Data and reproducible statistical analysis with Open








Figure 2: Oxford Knee Scores at baseline and at twelve months
follow-up. y-axis: Oxford Knee Score (OKS) for function value;
boxplot showing L-estimators: maximum (45), minimum (1),
median (25), and interquartile range (11); outliers plotted as
individual points at baseline and maximum (47), minimum (10),
median (33), and interquartile range (16); outliers plotted as
individual points at 1 year follow-up. x-axis: Oxford Knee Score
(OKS) for function at preoperative baseline and at twelve months
follow-up. Connecting lines: heuristic visualization of single-
patient trajectories of variation of Oxford Knee Score (OKS) value
for function between preoperative baseline and twelve months
follow-up; plotted with R (version 4.0.0 or higher; libraries ggpubr
and PairedData). Source: Authors’ Data and reproducible statistical






Figure 3: EQ-5D Scores at baseline and at twelve months follow-up.
y-axis: EQ-5D for quality of life score value; boxplot showing
L-estimators: maximum (0.812), minimum (-0.319), median
(0.62), and interquartile range (0.41); outliers plotted as individual
points at baseline and maximum (1), minimum (-0.074), median
(0.69), and interquartile range (0.28); Outliers plotted as individual
points at 1 year follow-up. x-axis: EQ-5D for quality of life score at
preoperative baseline and at twelve months follow-up. Connecting
lines: heuristic visualization of single-patient trajectories of
variation of EQ-5D for quality of life score value for function
between preoperative baseline and twelve months follow-up;
plotted with R (version 4.0.0 or higher; libraries ggpubr and
PairedData). Source: Authors’ Data and reproducible statistical
analysis with Open Access statistical software R (version 4.0.0
or higher).
Table 1: Variation of median VAS, OKS, and EQ-5D between
baseline and 12 months follow-up grouped by OA Grade.
oa_grade Count VAS OKS EQ-5D
1 1 ↑-48 ↑2 ↑0.2
2 12 ↑-54 ↑5.5 ↑0.14
3 20 ↑-28.5 ↑3.5 0
4 68 ↑-32.5 ↑7 ↑0.07
NA 9 ↑-17 ↑4 ↓-0.03
Legend: variation of median VAS, OKS, and EQ-5D between baseline and
twelve months follow-up has been grouped according to the grade of KOA.
VAS improvement is a reduction in score plotted in green and arrow-up.
All grades of OA show an improvement in pain as evidence by a reduction
in the median VAS score. OKS also improved in all grades of OA with the
most gains being made by those with the grade 4 group. EQ-5D
improvement is an increase in score plotted in green and arrow-up,
deterioration in red, and invariance in black. This shows a general trend in
all severity of KOA towards improvement, but these data are not suitable
for detailed subgroup analysis and statistical significance testing as grades 1
and 2 only represent 20% of the total group.
Source: Authors’Data and reproducible statistical analysis with Open Access
statistical software R (version 4.0.0 or higher).
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One patient with posttraumatic OA had an injury as a
child, and the other 3 had a combination of meniscal and
ACL injuries that then lead to KOA.
2.2. Source: Authors’ Data. Full and informed consent was
undertaken for each part of the procedure including sedation,
lipoasipration, and image-guided intra-articular injection.
All procedures were performed in an operating theatre as a
day case, and patients were discharged approximately three
hours following the completion of the procedure.
2.3. Harvesting the Adipose Tissue. The patient was placed
under a sedation administered by an anaesthetist. A small
incision was made to insert a 17G blunt cannula (connected
to a luer-lock 60-cc syringe), and Klein sterile solution
(containing saline, Lignocaine, and epinephrine) injected
into the subcutaneous fat. Approximately, 150-200ml of this
solution was injected in 50ml aliquots into the lower abdom-
inal area. Adipose tissue (approximately 50ml) was then
harvested manually via a 13G blunt cannula (connected to
a Vaclock 20ml syringe), by a consultant plastic surgeon,
experienced in this procedure. The area of fat harvest was
tailored to the body habitus of each patient, (normally lower
abdomen or flank areas) with the patient in a supine position.
An abdominal binder was then applied to the adipose tissue
harvest site.
2.4. Processing and Injecting the Lipoaspirate. The lipoaspi-
rate was processed using the Lipogems® system [29]. This is
a disposable and single-use device. The lipoaspirate is intro-
duced in a closed and aseptic manner into the low-pressure,
full immersion, transparent plastic cylindrical container
through stainless steel wire mesh. The device is prefilled with
saline. Within the container, there are stainless steel ball
bearings that work to mechanically fragment the fat, progres-
sively reducing the size of the clusters of adipose tissue (from
spheroidal clusters with a diameter of 1–3.5mm to clusters of
0.2–0.8mm) through mechanical agitation of the chamber
much like a cocktail shaker. The chamber is flushed with
saline to wash out impurities (e.g., oil, blood, and proinflam-
matory debris). The resulting product is then filtered through
a 500-micron filter. This process takes approximately 20
minutes. A single 6-8ml of this refined product was then
injected directly into the knee joint under ultrasound guid-
ance. This point of care device allows the procedure from
lipoaspiration to the injection of the microfragmented fat to
take place within the same sitting mitigating the need for
















































































































Figure 4: Missingness map. x-axis: outcome variables: gender, age, Visual Analogue Scale (VAS) for pain, Oxford Knee Score (OKS) for
function, and EQ5D for quality of life at preoperative baseline and three, six, and twelve months follow-up. y-axis: data points missing at
random (12%) due to patients lost-to-follow-up: missing data have been estimated probabilistically with uncertainty using the statistical
software package Amelia v1.7.6 or higher. The estimation procedure is replicable and reproducible with Open Access statistical software R
(4.0.0 or higher). The missingness map shows the missing data fields in our dataset. All patients have a preprocedure and 1 year VAS for
pain as seen on the right-hand column of the plot. The left-hand column then the missing OKS and EQ5D.
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2.5. Postoperative Care. All patients were provided with a
pack which included analgesia (paracetamol and codeine),
as well as a printed physiotherapy protocol. We advised our
patients to avoid nonsteroidal anti-inflammatory drugs.
Other nonpharmaceutical means of pain control such as rest
and the use of warm and cold packs were advocated. Follow-
ing discharge, outpatient physiotherapy sessions were sched-
uled for each patient. Patients were allowed to bear weight on
their joint postprocedure; however, they were instructed to
avoid any strenuous or high-impact activities for two weeks.
Chemical thromboprophylaxis was not prescribed.
2.6. Multiple Outcome Measurements. Outcomes were mea-
sured using the Visual Analogue Scale (VAS) for pain, the
Oxford Knee Score (OKS) for function, and the EQ5D for
quality of life. All patients completed these questionnaires
before treatment, and at three months, six months, and one
year following treatment. Our analysis in this report includes
the 12 months data.
VAS [30] is a validated measurement system that allows
participants to measure their pain intensity along a continu-
ous scale of values that otherwise cannot clearly be measured.
Participants are presented with a horizontal line that is
anchored by two extremes, between 0 and 100 (0 = no pain,
100 = worst pain), and are asked to place a point along the
VAS line at the point that would represent their current level
of pain.
OKS [31] comprised of 12 questions that were scored 0-4
with 0 being severe and 4 being none, covering pain and
function of the knee. The best outcome is a score of 48, and
the worst score possible is 0.
EuroQol-5 Dimension [32] is a standardized instrument
developed by the EuroQol Group in order to measure the
health-related quality of life in a wide range of medical con-
ditions. Five dimensions are measured in the respondent:
mobility, self-care, usual activity, pain, and anxiety/depres-
sion. Scores were given between 1 and -1; this was recorded
down with 1 being associated with a better quality of life
whilst -1 the opposite.
3. Results
3.1. Summary Results.Median VAS (pain) improved from 70
(IQR 20) at baseline to 30 (IQR 58) at twelve months
(p < 0:001); median OKS (function) improved from 25
(IQR 11) to 33.5 (IQR 16) (p < 0:001); and median EQ-5D
(quality of life) improved from 0.62 (IQR 0.41) to 0.69
(IQR 0.28) (p < 0:001). No adverse events were reported dur-
ing the intraoperative, recovery, or postoperative periods.
Summary results are presented in Table 3 and Figures 1,
2, and 3. Figure 5 shows the study flow diagram with the data
collection points of the study and attrition rate for collected
scores. The missingness map (Figure 4) presents where
scores have not been provided by the patients.
In Table 1, the variation of median VAS, OKS, and EQ-
5D between baseline and twelve months follow-up has been
grouped according to the grade of KOA. This shows a general
trend in all severity of KOA towards improvement, but these
data are not suitable for detailed subgroup analysis and statis-
tical significance testing as grades 1 and 2 only represented
20% of the total sample.
4. Discussion
We report here the results of treating degenerative arthritis of
the knee with autologous microfragmented adipose tissue.
We found that 81% of our patients experienced a reduction
in their pain and a concomitant improvement in their func-
tion with a single injection of MFAT. Median VAS, OKS,
and EQ-5D between baseline and twelve months follow-up
improved for all grades of KOA (Table 1). This shows a gen-
eral trend in all severity of KOA towards improvement, but
these data are not suitable for detailed subgroup analysis
and statistical significance testing as grades 1 and 2 only rep-
resent 20% of the total sample size. The risks of this proce-
dure are low and the possibility of reverting to more
interventional approaches in those who do not improve
remains. Of note is that higher grades of arthritis (KL grades
III and IV) demonstrated an improvement in pain and
function.
Knee OA is a debilitating condition that affects a signifi-
cant proportion of the population in all nationalities. Current
solutions include the correction of deformities to preserve the
knee or otherwise joint sacrificing procedures such as total or
partial replacement. These surgical options carry risk, and
many individuals seek nonsurgical solutions and are not will-
ing to consider surgery until these have been exhausted.
To this end, a growing number of clinicians are using
biologics such as Platelet Rich Plasma and cell-based
therapies to control pain in arthritis and delay the need for
surgical intervention. Among these therapies being investi-
gated is the use of microfragmented adipose tissue. A search

























of clinicaltrials.gov revealed a number of ongoing studies
assessing the effects of microfragmented adipose tissue
for KOA.
In our study, we noted a very low number of adverse
events and complications with pain at the harvest and
injections sites. This experience is mirrored in the literature
with a prospective study of 1524 patients, many with signifi-
cant medical comorbidities, who received stromal vascular
fraction procedures. At long term follow-up (22 to 64
months), 98% reported no adverse events and 0.72%
reported a new cancer diagnosis [33]. In a systematic review
and meta-analysis of 36 clinical trials of both autologous and
allogeneic mesenchymal stem cells harvested from several
tissue sources, there was no evidence of increased acute
toxicity, organ system complications, infection, death, or
malignancy [34].
More recently a number of clinical studies have demon-
strated the safety and efficacy of microfragmented fat for
the treatment of KOA. Russo et al. [35] reported on 30
patients who were treated with microfragmented fat as an
adjuvant for the surgical treatment of diffuse degenerative
chondral lesions, with a follow-up of three years. 22 required
no further treatment, and no adverse events were reported.
They also noted that the improvements in Tegner-Lysholm
Knee, VAS, IKDC-subjective, and total KOOS scores
observed at one year were maintained at the three-year mark.
Panni et al. [27] reported similar results with 52 patients
with early KOA, who received arthroscopic debridement
followed by injection of microfragmented fat. At final fol-
low-up, 96.2% of patients expressed satisfaction and reported
good or excellent improvements in function and/or pain.
Hudetz et al. [26] conducted a study where 20 patients with
KOA were treated with a single intra-articular injection of
microfragmented fat. He noted that 17 (85%) showed a sub-
stantial pattern of KOOS and WOMAC improvement, sig-
nificant in all accounts.
4.1. Study Limitations. Our experience has mirrored that of
many other colleagues regarding the use of MFAT in KOA.
This treatment offers a minimally invasive and nonsurgical
Eligible and VAS > 50 (n = 110)
VAS pre-procedure (n = 110)
VAS at 3 months (n = 108)
VAS at 6 months (n = 100)
VAS at 12 months (n = 110)
OKS pre-procedure (n = 105)
OKS at 3 months (n = 90)
OKS at 6 months (n = 78)
OKS at 12 months (n = 84)
EQ5D pre-procedure (n = 105)
EQ5D at 3 months (n = 89)
EQ5D at 3 months (n = 76)
EQ5D at 12 months (n = 81)
Injected with 8 mL MFAT
(n = 110)
Figure 5: Study flow diagram depicts the touch points including the preprocedure assessment, injection of the knee, and subsequent follow-up
and attrition in the collection of outcomes.
Table 3: Summary results.
Parameter Assessment Median score IQR score













1 year 0.69 0.28
Summary of the results showing the median values and Interquartile range (IQR) of Visual Analogue Scale for pain (VAS), Oxford Knee Score (OKS), and
EuroQuol 5D (EQ-5D) at baseline and at 1 year follow-up. A statistically significant improvement in all parameters is demonstrated with p < 0:001.
Source: Authors’ Data and reproducible statistical analysis with Open Access statistical software R (version 4.0.0 or higher).
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method for the treatment of KOA. The main limitation of
this study is the absence of a control group in our sample.
This self-selected group did not want to have major surgery
when they came to our clinic and were treated with an
ultrasound-guided single injection of MFAT. We included
all grades of arthritis but excluded those with deformity
greater than ten degrees. It can be argued that this represents
a heterogeneous group of disease. Combining the age range
of our cohort (42 to 94) as well as the severity of their condi-
tions (KL grade I-IV) makes for many variables and thus
makes subgroup analysis difficult. However, this is a prag-
matic representation of our clinical practice, and the highly
statistically significant improvement of pain, function, and
quality of life cannot be ignored.
The missingness map and study flow diagrams show an
attrition rate of 12% in our data collection. Responder fatigue
is a well-documented phenomenon and may introduce
bias [36].
5. Conclusions
The benefit of this treatment to the individual is in the
mitigation of complications and the associated recovery from
surgical intervention. The aim of any intervention is the
reduction in pain and improvement in function with a
resultant betterment of quality of life. The hope is that this
will then be reflected in the overall healthcare costs at a pop-
ulation level. Despite the limitations detailed above, our
study represents an incremental step in defining the place
for biologic treatments in degenerative joint disease. These
findings are mirrored in a number of other studies [26–28].
What remains unclear is whether true restoration of the car-
tilage occurs or indeed if this is necessary for the clinical
effects seen.
The authors caution that the retrospective nature of the
study and the small number of patients make it impossible
to draw definitive conclusions. The findings need to be vali-
dated with a randomized controlled trial, conducted over a
longer period to check for long-term outcomes, to establish
more clearly the stage of the disease best suited for treatment
with biologics in order to maximize patient-centered efficacy.
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